ReviewJournal of epidemiology and global health2024
Antimicrobial Resistance Profiles of Pseudomonas aeruginosa in the Arabian Gulf Region Over a 12-Year Period (2010-2021).
Review in Journal of epidemiology and global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Detection of carbapenem resistance mechanisms in difficult-to-treat Pseudomonas aeruginosa clinical isolates from a tertiary care hospital in Egypt.BMC microbiology · 2026Article
- Long-Term Trends in Antimicrobial Resistance Among Gram-Negative Clinical Isolates at Mubarak Al-Kabeer Hospital, Kuwait (2007-2022).Antibiotics (Basel, Switzerland) · 2026Article
- Effect of Extremely Low-Frequency Pulsed Electromagnetic Field Intensity and Exposure Time onMicroorganisms · 2026Article
- Unveiling a new sequence type in high-risk clonal complexes of virulent carbapenem-resistant Pseudomonas aeruginosa carrying blaBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Longitudinal trends in antimicrobial resistance phenotypes inFrontiers in antibiotics · 2026Article
- Molecular Characterization of Cocarriage Carbapenemase Genes in ClinicalInternational journal of microbiology · 2026Article
- Antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam, and comparators against Gram-negative pathogens collected in Arabian Gulf countries: SMART 2020-2024.Frontiers in cellular and infection microbiology · 2026Article
- Colistin use and outcomes in Kuwait public hospitals.Frontiers in drug safety and regulation · 2026Article
- Feasibility Study on Risk Stratification for Multidrug-Resistant Organism Infections Among ICU Patients in the United Arab Emirates.Risk management and healthcare policy · 2026Article
- In vitro and in vivo investigation of the antibacterial, antivirulence, and antiquorum sensing activities of β-carotene against difficult-to-treat resistant Pseudomonas aeruginosa.BMC microbiology · 2025Article
- Microbial prevalence and understanding of their antimicrobial susceptibility in urinary tract of patients attending at shar teaching hospital (2018-2022).BMC research notes · 2025Article
- Activity of cefiderocol on extensively drug-resistantIranian journal of microbiology · 2025Article
- Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-ResistantPharmaceuticals (Basel, Switzerland) · 2025Article
- Microbial Colonization and Antibiotic Resistance Profiles in Chronic Wounds: A Comparative Study of Hidradenitis Suppurativa and Venous Ulcers.Antibiotics (Basel, Switzerland) · 2025Article
- Development and Evaluation of a Handmade Lateral Flow Immunoassay for the Rapid Detection of Carbapenem-producing Gram-Negative Bacteria in China.Infection and drug resistance · 2025Article
- A decade of antimicrobial resistance trends inFrontiers in microbiology · 2025Article
- Article
- Structural insights into alterations in the substrate spectrum of serine-β-lactamase OXA-10 fromEmerging microbes & infections · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate literature from a 12-year period (2010-2021) on the antimicrobial resistance profile of Pseudomonas aeruginosa from the Arabian Gulf countries (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates).
methodsAn electronic literature search was conducted for articles on antimicrobial resistance in P. aeruginosa and associated phenotypes, covering the period of 1st January 2010 to 1st December 2021.
resultsAntimicrobial resistance in the Arabian Gulf was highest to meropenem (10.3-45.7%) and lowest to colistin (0.0-0.8%), among the agents tested. Annual data showed that ceftazidime resistance (Kuwait), piperacillin-tazobactam non-susceptibility (Qatar), and aztreonam, imipenem, and meropenem resistance (Saudi Arabia) increased by 12-17%. Multiple mechanisms of carbapenem resistance were identified and multiple clones were detected, including high-risk clones such as ST235. The most common carbapenemases detected were the VIM-type metallo-β-lactamases.
conclusionsAmong P. aeruginosa in the Arabian Gulf countries, resistance to meropenem was higher than to the other agents tested, and meropenem resistance increased in Saudi Arabia during the study period. Resistance to colistin, a classic antibiotic used to treat Pseudomonas spp. infections, remained low. The VIM-type β-lactamase genes were dominant. We recommend local and regional antimicrobial resistance surveillance programs to detect the emergence of resistance genes and to monitor antimicrobial resistance trends in P. aeruginosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.